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In about 20–30% of phenylketonuria (PKU) patients, phenylalanine (Phe) levels can be controlled by cofactor 6R-
tetrahydrobiopterin (BH4) administration. The phenylalanine hydroxylase (PAH) genotype has a predictive value
concerning BH4-response and therefore a correct assessment of the mutation molecular pathology is important.
Mutations that disturb the splicing of exons (e.g. interplay between splice site strength and regulatory sequences
like exon splicing enhancers (ESEs)/exon splicing silencers (ESSs)) may cause different severity of PKU. In this
study, we identiﬁed PAH exon 11 as a vulnerable exon and used patient derived lymphoblast cell lines and
PAH minigenes to study the molecular defect that impacted pre-mRNA processing. We showed that the
c.1144T>C and c.1066-3C>T mutations cause exon 11 skipping, while the c.1139C>T mutation is neutral or
slightly beneﬁcial. The c.1144T>Cmutation resides in a putative splicing enhancermotif and binding by splicing
factors SF2/ASF, SRp20 and SRp40 is disturbed. Additional mutations in potential splicing factor binding sites
contributed to elucidate the pathogenesis of mutations in PAH exon 11.
We suggest that PAH exon 11 is vulnerable due to a weak 3′ splice site and that this makes exon 11 inclusion
dependent on an ESE spanning position c.1144. Importantly, this implies that other mutations in exon 11
may affect splicing, since splicing is often determined by a ﬁne balance between several positive and negative
splicing regulatory elements distributed throughout the exon. Finally, we identiﬁed a pseudoexon in intron
11, which would have pathogenic consequences if activated by mutations or improved splicing conditions.
Exonicmutations that disrupt splicing areunlikely to facilitate response toBH4andmay lead to inconsistent genotype–
phenotype correlations. Therefore, recognizing such mutations enhances our ability to predict the BH4-response.
© 2012 Elsevier Inc. All rights reserved.
1. Introduction
Hyperphenylalaninemia (HPA) is the result of a defect in the hy-
droxylation of phenylalanine (Phe) to tyrosine (Tyr) [1]. The reaction
is catalyzed by phenylalanine hydroxylase (PAH, EC 1.14.16.1) requir-
ing the essential cofactor tetrahydrobiopterin (BH4) [2]. In the major-
ity of cases hyperphenylalaninemia (HPA) is caused by mutations in
the PAH gene, resulting in different phenotypes classiﬁed according
to Phe levels in the blood ranging from mild HPA, mild PKU to classic
PKU. PKU is a very heterogeneous disease and belongs to the most
common inherited diseases in amino acid metabolism [3]. As elevated
Phe levels cause severe brain damage, it is compulsory to start treat-
ment as early as possible.
Over 500 mutations have been reported in the coding sequence as
well as in the intervening sequence of the PAH gene (Online database,
http://www.pahdb.mcgill.ca/) [4]. More than half of these are classiﬁed
as missense changes. Several PKU mutations have been shown to affect
protein folding, thereby causing accelerated degradation and/or aggrega-
tion [5]. The measurement of enzymatic activities in vitro of mutant pro-
teins can generally be useful in predicting HPA's, but it has also been
suggested that up to 50% of exonic mutations may perturb pre-mRNA
splicing, thereby leading to more deleterious effects on protein function,
irrespective of the predicted amino acid change [6].
In 20-30% of PKU patients (all phenotypes), Phe levels may be con-
trolled through BH4 (sapropterin dihydrochloride [7]) therapy [8]. Only
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the patient's full genotype determines BH4-repsonsiveness [9,10], but
genotype–phenotype correlations are not always reliable as discordant
results have been observed between patients with common genotypes
[11]. Exonic mutations that disrupt splicing are unlikely to facilitate
BH4-response and recognizing such mutations enhances our ability to
predict BH4‐responsiveness. It is therefore important to correctly assess
the molecular pathology of PAHmutations.
Cis-acting elements such as exon splicing enhancers (ESE) or exon
splicing silencers (ESS) participate in exon recognition in a ﬁnely bal-
anced interplay with splice site strengths and this ﬁne balance can be
disturbed through deleterious effects of mutations in these elements.
When bound to ESEs serine/arginine-rich proteins (SR proteins) pro-
mote exon deﬁnition by directly recruiting the splicing machinery
through their RS domain and/or by antagonizing the action of nearby
silencer elements [12].
Relatively few studies have investigated mRNA processing defects
owing to exonic sequence variation in the PAH gene. The mutation
c.611A>G, putatively p.Y204C, was investigated for a role in mRNA pro-
cessing when in vitro assessment of themutant enzyme did not demon-
strate signiﬁcantly reduced activity and correspond to the phenotype in
the PKU patients [13]. Analysis of the PAH mRNA in a patient lympho-
blast cell line showed that the c.611A>G mutation masquerades as a
missense mutation, but actually creates a new 5′ splice site resulting in
a 96nt deletion at the 3′ end of PAH exon 6. This study, together, with
the ﬁnding that a synonymous mutation, c.1197A>T, causes exon 11
skipping instead of being neutral [14] and our recent study of a
c.30C>G synonymous mutation, which creates an ESS [15] with unex-
pected effects on mRNA splicing, shows that more detailed analysis of
PAH pre-mRNA processing may be required to determine a mutation's
molecular pathology which ultimately may relate to both the patient's
phenotype and the possibility of BH4-response. Herein, we established
and validated a PAH exon 11minigene, which allows testing the impact
of PAH exon 11 missense and splice site mutations on mRNA splicing.
Both natural mutations and several artiﬁcial mutations were investigat-
ed to gain insight into the splicing mechanism of PAH exon 11. The pa-
thology of the two exonic mutations, c.1139C>T and c.1144T>C, was
analyzed by transfection of the minigene reporter, by RNA afﬁnity puri-
ﬁcation and results were conﬁrmed by analysis of patient cell lines.
2. Materials and methods
2.1. Patient specimens
Patient samples analyzed in this work were previously reported
among a large cohort of Turkish PKU patients [10]. Table 1 summa-
rizes the genotypes and phenotypes of the 4 patients analyzed in
this study. Patient with a mild HPA, have been identiﬁed as BH4-
responsive by the oral loading test.
2.2. Generation of patient cell lines and cell culture
Peripheral blood lymphocytes from PAH deﬁcient patients were
transformed with Epstein–Barr virus [16] to generate lymphoblast
cell lines. Lymphoblast cell lines and Chang human liver epithelial
cells were cultured in RPMI 1640 (Sigma Aldrich, St. Louis, MO,
USA) and 5% fetal calf serum. COS-1 cells were cultured in Dulbecco's
Modiﬁed Eagle's Medium (DMEM, Sigma) with 10% fetal calf serum.
To perform nonsense-mediated mRNA decay analysis, lympho-
blast cells were cultured overnight in presence of 10 μg cyclohexi-
mide (Sigma) prior to mRNA extraction.
2.3. Minigene construction
Initially, a 1946-bp fragment of human PAH including exon 10, intron
10, exon 11, intron 11 reduced to 988 bp and exon12was synthesized by
GenScript (NJ, USA). A start codon was added to exon 10 and a KpnI site
was removed from intron 10 to facilitate cloning. In addition, intron 11
was extended by inserting at an EcoRI site a PCR ampliﬁed 963 bp frag-
ment ampliﬁed using AccuPrime Pfx SuperMix (Invitrogen). Five unique
minigene constructswere prepared:WT, c.1139C>T, c.1144T>C, c.1066-
3C>T and c.1197A>T. The minigenes were cloned into the polylinker of
pcDNA3.1+ vector (Invitrogen) by using KpnI and XhoI restriction en-
zymes. The correct insertion was veriﬁed by sequencing with BigDye
Terminator Cycle sequencing v1.1 (Applied Biosystems) on an ABI
Prism 3100 Sequencer.
Othermutations used for the characterization of eventual splicing
regulatory elements caused by the mutations of interest were either
introduced by site-directed mutagenesis with QuikChange XL II kit
(Agilent Technologies, CA, USA) or ordered from GenScript. These
nucleotide changes include: c.1139C>A, c.1139C>G, c.1144T>A,
c.1144T>G, c.1169A>G, c. 1146C>A, c.1144C+1146A, c.1139T+
1144C, c.1144_1146delTTC and the insertion of a known wild type
and mutant ESE sequence from the ACADM gene [17].
2.4. Transient transfection experiments
Transient transfection experiments were conducted with FuGENE 6
Transfection reagent (Roche Applied Biosciences) as described [17].
Chang or COS-1 cells were seeded at 2×105 (resp. 3×105) cells per
35 mm well and transfected with 0.8 μg of minigene construct DNA.
Co-transfections with the vectors for SF2/ASF, SRp40 (generous gifts
from Adrian Krainer, Cold Spring Harbor, NY), hnRNPH (generous gift
from Mark McNally, University of Wisconsin) and hnRNPA1 (generous
gift from Benoit Chabot, University of Sherbrooke, Canada) were per-
formed as described [17]. After 48 h, cells were harvested in 300 μl
RLT buffer and stored at−80 °C for either later processing or RNA ex-
traction was continued according to the manufacturer's protocol of
Qiagen RNA blood mini kit.
2.5. Analysis of RNA processing
Analyses of illegitimate PAH transcripts from patient lymphoblasts
were performed according to previously described methods [18].
After harvesting, total RNA was extracted from patient lymphoblast
cell lines using Qiagen RNA blood mini kit. One microgram of isolated
RNA was reverse-transcribed with iScript™ cDNA Synthesis kit
(BioRad, CA, USA) containing a mix of Oligo (dT) and random
hexamer primers. The cDNA from patient lymphoblasts covering
exons 9–13 was PCR-ampliﬁed using primers PAHX9fwd (5′-TG-
GCCTTGCCTCTCTGGGTGC-3′) and PAHDrev (5′-GACCACATTCTGTCC-
ATGGCTTTA-3′).
Ampliﬁcation of PAH from the minigenes was performed with a
minigene-speciﬁc primer pair to exclude detection of endogenous PAH:
forward primer 11s2 (5′-GGTAACGGAGCCAACATGGTTTACTG-3′) and
reverse 11as (5′-AGACTCGAGGGTAGTCTATTATCTGTT-3′). The ampliﬁ-
cation products were analyzed by 1% agarose gel electrophoresis. PCR
products were gel extracted, puriﬁed and sequenced using the BigDye
Terminator Cycle sequencing v1.1 (Applied Biosystems) on an ABI
Prism 3130xL Sequencer.
Table 1
Summary of genotype and phenotype of PKU patients analyzed in this work.
Genotype Variation Phenotype
1. c.1066-3C>T/c.1066-3C>T IVS10-3C>T/IVS10-3C>T Mild HPA
2. c.1066-3C>T/c.1208C>T IVS10-3C>T/p.A403V Mild HPA
3. c.1144T>C/c.1144T>C p.F382L/p.F382L Mild HPA
4. c.1139C>T/c.898G>T p.T380M/p.A300S Mild HPA
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2.6. RNA oligonucleotide afﬁnity puriﬁcation
The afﬁnity puriﬁcation of RNA binding proteins utilized 3′-biotin-
labeled RNA oligonucleotides as described (DNA Technology Denmark)
[15]. For each puriﬁcation 100 pmol of RNA oligonucleotide was
coupled to 100 μl of streptavidin-coupled magnetic beads (Invitrogen)
and incubated with HeLa nuclear extract (Cilbiotech S.A., Belgium)
[17]. After washing, bound proteins were investigated by western blot-
ting using a monoclonal mouse antibody SF2/ASF (AK96 from Zymed
Laboratories (Invitrogen)), SRp40, SRp20, hnRNPH or hnRNPA1 (sc-
33418, sc-13510, sc-10042 and sc-10029 — Santa Cruz Biotechnology,
Santa Cruz, CA).
2.7. Expression of PAH proteins and activity assay
PAH activities were determined using a novel mass spectrometry
method for quantiﬁcation of Phe and Tyr in cell lysates [19]. Mutations
in the human PAH cDNA sequence in pCMV-FLAG-PAHwere introduced
by site-directed mutagenesis using QuikChange XL II kit from Agilent
Technologies (Santa Clara, CA, USA) and conﬁrmed by DNA sequence
analysis. Expression plasmids were transfected into COS-1 cells using
FuGENE 6 (Roche Applied Biosciences) and harvested after 48 h.
Cell lysates were prepared and enzyme activity was determined
using previously described methods. The amount of Tyr produced
was determined by LC ESI-MSMS.
Protein concentrations of all sample types were determined using
Pyrogallol Red protein dye binding assay [20]. Speciﬁc PAH activities
are expressed in mU/mg total protein, with mU equal to nmol Tyr
produced per min.
3. Results
3.1. PAH exon 11 is ﬂanked by a weak 3′ splice site
We initially assessed the strength of all splice sites in the PAH gene
to identify exons that are weakly deﬁned and thus vulnerable to mu-
tations affecting splicing regulatory elements [12]. Table 2A displays
all splice sites of the 13 exons of the PAH gene and the calculated
strengths using the maximum entropy model (MaxEntScan http://
genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html) which
showed that exon 11 is vulnerable with a weak 3′ splice site. The
c.1066-3C>Tmutation, which is located in the 3′ splice site has previ-
ously been demonstrated to result in exon 11 skipping [18], although
this change only modestly weakens the score (3.16 to 2.11, Table 2B)
and themutant splice site retainswithin the splice site consensus. More-
over, c.1197A>T, an exonic mutation that only decreases the MaxEnt
score of the 5′ splice site from 9.16 to 7.65 has also been reported to
cause exon 11 skipping [14]. Together these data indicated that exon 11
isweakly deﬁned and is likely to be dependent on exonic splicing enhanc-
er sequences. We therefore hypothesized that mutations in exon 11
might disrupt the ﬁne balance between exonic splicing enhancers (ESE)
and exonic splicing silencers (ESS) and thus result in exon 11 skipping.
We decided to investigate some of the missense mutations reported to
be BH4 responsive.
3.2. Aberrant PAH splicing in patient lymphoblast cell lines
PAH pre-mRNA processing was investigated using patient derived
lymphoblast cell lines. RT-PCR was used to amplify a fragment from
PAH exon 9 to the end of the coding region. In patients 1, 2 and 3
the expected 463 bp fragment was observed along with a 329 bp frag-
ment (Fig. 1A). This alternative product is most pronounced in patient
1 who is homozygous for the c.1066-3C>T mutation. DNA sequence
analysis of the puriﬁed 329 bp band showed that exon 11 was miss-
ing. This analysis indicates that the c.1066-3C>T and c.1144T>C mu-
tant alleles cause exon 11 skipping in patient cells.
Skipping of exon 11 results in deletion of 134 bp from the PAHmRNA
leading to a shifted reading frame and replacement of the 97 C-terminal
codons with 21 missense codons followed by three in frame premature
stop codons in exon 12, which is the penultimate exon of the PAH gene.
The ﬁrst premature stop codon in exon 11 skipped PAHmRNA is located
53 nucleotides upstreamof the last exon–exon junction. This corresponds
to the required minimal distance (50–55 nt) upstream of the last exon,
which typically triggers degradation of the premature stop codon con-
taining mRNA by the Nonsense Mediated Decay (NMD) system [21].
There are, however, examples where NMD is triggered by premature
stop codons located even closer to the last exon–exon junction [21]. To
determine whether NMD is degrading the aberrantly spliced PAH
mRNA, we treated patient cells overnight with cycloheximide (CHX), to
block NMD. Assessment of PAHmRNA following CHX treatment showed
a dramatic increase in the 329 bp cDNA product lacking exon 11 which
demonstrates that the aberrantly spliced PAH mRNA is degraded by
NMD (Fig. 1B). The presence of the full length product conﬁrms that the
c.1139C>T mutant allele does not lead to exon 11 skipping.
TheminorDNA speciesmigrating close to thewild type transcript is a
heteroduplex formed between cDNA strands of the wild type and exon
11 deleted mutant. This was conﬁrmed by sequencing.
3.3. Minigene analysis conﬁrms results from patients' lymphoblasts
To further elucidate the molecular mechanism of aberrant PAH exon
11 splicing and to enable testing of exon 11 mutations where cell lines
are not available, a PAHminigenewas constructed. Theminigene harbors
exons 10, 11 and 12, with intron 10 and a shortened intron 11 (Fig. 2A).
We tested the exon 11 mutations c.1066-3C>T, c.1139C>T, c.1144T>C,
in addition to c.1197A>T that was previously reported to cause exon 11
skipping [14,22] and c.1169A>G which is a prevalent BH4 responsive al-
lele in the Turkish population [10]. Analysis of COS-1 cells transfected
with the minigenes shows that the mutations c.1197A>T, c.1144T>C
and c.1066-3C>T lead to exon 11 skipping, whereas the c.1169A>Gmu-
tation is neutral and the c.1139C>T mutation seems to have a slightly
positive effect on exon 11 inclusion (Fig. 2B). These results are consistent
with our analysis of the patient cells andunderline that the splicing of PAH
Table 2A
PAH splice site strength.
Intron 5′ splice site ME score 3′ splice site ME score
1 cagGTgagc 9.60 aaatgcatcttatcctgtAGgaa 8.00
2 gagGTcagt 7.70 ctccccattctctcttctAGgag 11.78
3 cagGTaaga 10.77 ttgccttctctgtgtttcAGtgc 11.04
4 cctGTgagt 7.21 aggtgtctcttttctcctAGggt 8.81
5 ccaGTgagt 8.28 attttgtgcctgtattctAGtgg 7.29
6 agaGTaagt 9.35 ctttcttcttttcatcccAGctt 7.65
7 accGTgagt 9.40 ctgtgctttctgtctttcAGtga 11.57
8 cagGTaagg 11.08 ctattttcccccaattacAGgaa 9.51
9 acaGTaagt 9.49 agattgactttccattccAGatt 7.71
10 cagGTatga 9.46 ttttcacttggggcctacAGtac 3.16
11 aagGTgagg 9.16 gcctgtggttttggtcttAGgaa 8.92
12 acaGTaagt 9.49 gatggtgtttttctttgtAGgtg 10.48
5′ splice site 9mer, 3′ splice site 23mer, maximum entropy scores from http://
genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html.
Table 2B
Maximum entropy (ME) score variation for 3′splice site of PAH exon 11 upon c.1066-
3C>T mutation.
Intron Mutation 3′ splice site ME score
10 Wild-type (c.1066-3C) ttttcacttggggcctacAGtac 3.16
10 c.1066-3T ttttcacttggggcctatAGtac 2.11
10 c.1066-3T opt. ttttcacttttttcctatAGtac 8.52
10 Wild type opt. ttttcacttttttcctacAGtac 9.58
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transcripts from our minigene mimics that of the endogenous PAH gene.
In addition, the minigene analysis conﬁrms that the c.1197A>T,
c.1144T>C and c.1066-3C>T mutations compromise splicing and that
the observed mis-splicing in patient cells does not result from a linked
mutation located outside the sequenced region of the gene or from the
other mutant allele present in the compound heterozygous patients.
The minigene analysis also indicates that splicing of wild type PAH exon
11 results in small amounts of exon 11 skipping, consistent with the
fact that it is weakly deﬁned and dependent on ESE's [12].
As PAH is primarily expressed in the liver, we also transfected
Chang cells with PAH minigene constructs. A higher degree of mis-
splicing of the c.1144T>C minigene (Fig. 2C) was observed, but the
   Cont         c.1066-3C>T   c.1208C>T     c.1144T>C     c.898G>T
Exon  9 10 11 12 13
10 1312Exon  9 
Exon  9 10 11 12 13
10 1312Exon  9 
                    c.1066-3C>T  c.1066-3C>T  c.1144T>C    c.1139C>T 
c.898G>T
 -------               CHX              -------               CHX             -------             CHX  
c.1066-3C>T                        c.1144T>C                           







Fig. 1. PAH pre-mRNA splicing analysis in patient lymphoblast cells. Cells from control and patients were analyzed with and without blockage of NMD by CHX treatment. Genotypes:
Patient 1: c.1066-3C>T/c.1066-3C>T, Patient 2: c.1066-3C>T/c.1208C>T, Patient 3: c.1144T>C/c.1144T>C, Patient 4: c.1139C>T/c.898G>T. (A) Comparison of PAH mRNA tran-
script from lymphoblast patient cells by ampliﬁcation of exons 9–13. (B) Comparison of PAH transcript from lymphoblast patient cells treated with 10 μg cycloheximide (CHX).





Fig. 2. PAH pre-mRNA splicing in COS-1 and Chang cells transfected with PAH minigenes.(A) Schematic description of the PAH minigene harboring exons 10 to 12. Start and stop
codons were added to complete the reading frame. (B) Analysis of COS-1 cells transfected with minigenes harboring WT, c.1139C>T, c.1144T>C, c.1066-3C>T, c.1169A>G and
c.1197A>T mutations. (C) Analysis of transfection in Chang liver cells with minigenes harboring WT, c.1139C>T, c.1144T>C and c.1066-3C>T mutations. (D) Analysis of COS-1
cells transfected with minigenes harboring WT, c.1144T>C and c.1066-3C>T mutations with and without an optimized 3′ splice site. Ampliﬁcation of PAH exons 10–12 was
done with minigene-speciﬁc primers. Transfection experiments were performed as at least two independent transfections.
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degree ofmis-splicingwas inconsistent between separate transfection ex-
periments. As such, COS-1 cells were used in subsequent experiments.
The results from Chang cells indicated that the c.1144T>C mutation
may result in different degrees of mis-splicing varying from complete
skipping to the same degree of skipping as observed in the COS-1 cells.
This also illustrates that the degree of mis-splicing may vary depending
on the cell type.
Heteroduplex formation of wild type and exon 11 deleted mutant
cDNAs was conﬁrmed by sequencing in both cell lines.
3.4. Correction of the 3′ splice site of exon 11 by mutagenesis
To investigate the contribution of the weak 3′ splice site to exon skip-
ping in PAH exon 11, the 3′ splice site was optimized. The four guanosine
nucleotides (c.1066-8 to c.1066-11) that interrupt the polypyrimidine
tractwere replacedwith thymidines. This substitution increased themax-
imum entropy score from a weak 3.16 to a robust 9.58. In the wild type
minigene construct, improved exon 11 inclusion was observed
(Fig. 2D). Moreover, when the optimized polypyrimidine tract is included
in the c.1066-3C>T and c.1144T>C constructs, aberrant splicing is no lon-
ger observed. At position−3 upstream of the 3′ splice site, a thymidine
base is considered to match the consensus motif. PAH exon 11 skipping
owing to the c.1066-3C>T mutation is an indication to the weakness of
the splice site owing to guanosine bases at−8 to−11. Amelioration of
mis-splicing owing to c.1144T>C with the corrected polypyrimidine
tract suggests that the c.1144T>C mutation disrupts the function of an
ESE, which is required for recognition of the weak 3′ splice site.
3.5. The c.1144T>Cmutation disrupts an ESE,which is required for inclusion
of PAH exon 11
The c.1144T>C mutation causes exon 11 skipping. To elucidate
whether the mechanism underlying pre-mRNA mis-splicing is owing to
the disruption of an ESE or creation of an ESS in the minigene constructs,
various proportions of the sequence surrounding position c.1144 were
deleted (Fig. 3A). Minigenes with a 9 bp deletion (c.1141 to c.1149)
showed complete exon 11 skipping, whereas the 6 bp deletion (c.1144
to c.1149) has a slightly less dramatic effect, and the 3 bp deletion
(c.1144 to 1146) has a minor deleterious effect on exon 11 inclusion
(Fig. 3B). This shows that an ESE element is located in this region of
exon 11, but it may also suggest that this ESE is complex and may bind
more than one splicing factor, since 6 bp and 9 bp had to be deleted in
order to completely abolish splicing. Alternatively, the 3 bp deletion rec-
reates an ESE sequence (see below). To further characterize this putative
ESE, we analyzed the wild type and mutant sequences with the Human
Splicing Finder (HSF) program (http://www.umd.be/HSF/HSF.html) and
made site speciﬁc mutations in the region. The HSF program suggested
that the c.1144T>C mutation disrupts a TTCCAG(C) ESE, which could be
a binding site for the splicing stimulatory factor SRp40 (SRSF5).Moreover,
the HSF program also suggested that a TTCCAGmotif, which is a putative
ESE [23] is disrupted both by the c.1144T>Cmutation and the c.1146C>A
mutation, but that the c.1144T>C/c.1146C>A double mutation creates a
new ESE AGCTAC. These predictions were consistent with our minigene
analysis (Fig. 3B) and suggest that the TTCCAG sequence functions as an
ESE, perhaps by binding of SRp40 (SRSF5) and/or other factors. The HSF





Fig. 3. PAH pre-mRNA splicing in COS-1 cells transfected with PAHminigenes.(A) Sequences showing the precise location of the deletions and the inserted MCAD ESE. (B) Analysis
of COS-1 cells transfected with minigenes harboring WT, 3 bp, 6 bp and 9 bp deletions and analysis of COS-1 cells transfected with minigenes harboring WT, c.1144T>C, c.1146C>A
and c.1144T>C+c.1146C>A mutations. (C) Analysis of COS-1 cells transfected with minigenes harboring WT and all possible nucleotide variations at positions c.1139 and c.1144.
(D) Analysis of COS-1 cells transfected with minigenes harboring WT, c.1139C>T, c.1144T>C, c.1139C>T+c.1144T>C mutations and analysis of COS-1 cells transfected with mini-
genes harboring WT and substitutions with wild type and mutant MCAD ESE sequences. Ampliﬁcation of PAH exons 10–12 was done with minigene-speciﬁc primers. Transfection
experiments were performed as at least two independent transfections.
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this TTCCAG motif it also recreates several potential ESE sequences,
explaining the lack of a dramatic effect from this mutation. Consistent
with our transfection results HSF analysis suggested a deleterious impact
of both the 6 bp and the 9 bp deletions. Moreover we also mutated posi-
tions c.1139 and c.1144 to all possible substitutions and also created a
double mutation. Interestingly, this showed that c.1139C>G and
c.1144T>G both cause skipping and that introduction of the c.1139C>T
mutation together with the c.1144T>C mutation compensates for the
splicing defect (Figs. 3C, D). These data were not consistent with the
HSF analysis predictions and may contradict that the ESE functions by
binding of SRp40 and they suggest that the c.1139C>T mutation has a
positive effect on splicing.
Finally, we substituted the PAH ESE region with a functional ESE
from the ACADM gene [17], which has been demonstrated to function
in several other genes [17,24]. Surprisingly, the wild type MCAD ESE
could only partly substitute the PAH ESE sequence. As expected themu-
tated MCAD ESE was also non-functional in the PAH context (Figs. 3A,
D).
Taken together our data are consistent with a model where the
c.1144T>C mutation causes exon 11 skipping by disrupting the func-
tion of an ESE, which is required for recognition of the weak 3′ splice
site.
3.6. Analysis of the PAH exon 11 ESE by RNA afﬁnity puriﬁcation
To identify proteins that bind the PAH exon 11 ESE, RNA afﬁnity puri-
ﬁcation was performed. RNA oligonucleotides containing c.1139C>T and
c.1144T>C mutant sequences were incubated in HeLa cell nuclear ex-
tracts (Fig. 4). Western blot analysis showed strong binding of SF2/ASF
(SRSF1) to the WT sequence, which was abolished by both the
c.1139C>T and c.1144T>C mutant sequences. While factor binding was
less robust for SRp20 (SRSF3) and SRp40 (SRSF5) the same pattern was
observed. No difference was observed for binding of hnRNPA1. This may
indicate that c.1144T>C causes exon 11 skipping by disrupting binding
of an SR protein to an ESE motif that includes c.1144. However, it is not
clear, if all three SR proteins bind an identical sequence motif or if they
bind overlapping motifs, which are all disrupted by the c.1144T>C
mutation. Alternatively one SRproteinmaybind theRNAwhile the others
are associated via protein–protein interaction through their RS-domains.
Moreover, it is unclear why binding of SR proteins is disrupted by
c.1139C>T, as thismutation is shown to improve splicing in ourminigene
studies (see Figs. 2 and 3). This could, however, be due to steric hindrance
by binding of another protein to the new ESE created by the c.1139C>T
mutation. In support for this notion, we observed increased binding of
hnRNPH to the c.1139C>T sequence and this would block binding of
the SR proteins to the ﬂanking ESE harboring position c.1144. The
hnRNPH protein is, however, typically a negative regulator of splicing
[15].
Further analysis is required in order to identify conclusively the in-
volved splicing regulatory proteins that bind the exon 11 ESE.
3.7. Co-transfection with splicing factors leads to change in splicing
pattern
Because the RNA afﬁnity studies had suggested a possible role for
SF2/ASF (SRSF1) and SRp40 (SRSF5) in binding to the ESE, we per-
formed co-transfection of the PAH minigenes with expression plas-
mids for SF2/ASF (SRSF1) or SRp40 (SRSF5) human proteins to see if
the mutant ESE could be compensated by increasing the amounts of
these SR proteins. However, instead of correcting splicing, over-
expression of SF2/ASF (SRSF1) resulted in strong activation of a previ-
ously unknown pseudoexon (exon 11a) comprising 286 bp of intron
11 and severely reduced inclusion of exon 11 (Figs. 5A, B and Supple-
mentary Figs. S1, S2). The c.1139C>T mutant minigene had slightly
less pseudoexon inclusion, consistent with the fact that this mutation
results in improved splicing, possibly because it creates a new ESE,
which results in stronger deﬁnition of exon 11. In line with this,
pseudoexon inclusion in response to SF2/ASF (SRSF1) overexpression
was nearly abolished when the weak 3′ splice site is improved, show-
ing that this pseudoexon activation is only possible because exon 11
is weakly deﬁned (Fig. 5C).
Similar results as above were obtained from co-transfecting the dif-
ferent minigenes with SRp40 (SRSF5) (Supplementary Fig. S1). Co-
transfection of hnRNPA1 and hnRNPH, two negative regulators of splic-
ing, did not result in changes in splicing pattern or splicing efﬁciencies
(data not shown).
When patient cells are treated with cycloheximide, the new exon
11a can be ampliﬁed from the patient's cDNA using an exon 11a spe-
ciﬁc primer (Supplementary Fig. 2). This shows that the pseudoexon
inclusion is not merely an artifact produced only from the minigenes,
but that some level of pseudoexon inclusion is possible from the en-
dogenous PAH gene, although the relevance of this is unclear. The
pseudoexon could have deleterious effects if it is activated by muta-
tions or by improved splicing conditions.
3.8. Enzyme activities of c.1139C>T and c.1144T>C are reduced compared
to wild type PAH
The expression of c.1139C>T (p.T380M) and c.1144T>C (p.F382L)
mutant proteins showed reduced activities compared to wild type
PAH protein (Supplementary Fig. S3). Residual activity for mutant
p.T380Mwas found to be 38% of wild type activity, whereas p.F382L ac-
tivity was lower with 18%. Patients with these mutations exhibit a mild
phenotype, which is in accordance with residual PAH activity of 25%.
The p.F382L mutant has previously been expressed in a eukaryotic
expression system with a residual activity of 56%. But in this case, the
amino acid change was caused by c.1146G [25].
4. Discussion
Correlation between genotype and disease phenotype is fundamen-
tal to inform about treatment in inherited diseases. The utility of PAH
Fig. 4. RNA oligonucleotide afﬁnity puriﬁcation. RNA oligonucleotide afﬁnity puriﬁcation
of HeLa nuclear extracts using oligonucleotides with WT, c.1139C>T and c.1144T>C se-
quences followed byWestern blot analysis.
408 C. Heintz et al. / Molecular Genetics and Metabolism 106 (2012) 403–411
genotyping is increasingly relevant as efﬁcient newborn screening is a
facilitator of patients having their ﬁrst clinic visit often within the ﬁrst
week of life. As Phe levels in early identiﬁed patients will not have
reached peak concentrations, discerning disease phenotype often relies
on the PAH genotype. The PAH genotype may also inform on the utility
of BH4 therapy. Furthermore, in vitro biochemical characterization of
missensemutationsmay provide clues as to the efﬁcacy of BH4. Howev-
er, in recent years it has become increasingly clear that a so called “splic-
ing code” is also in operation andmutations in the coding sequencemay
affect pre-mRNA processing and thus overrule what can be predicted
based on assumed amino acid substitutions. The splicing code is poorly
deﬁned, but it is clear that not all exons are equally subject to aberrant
splicing by mutations affecting cis-acting splicing regulatory elements.
The so-called “weak exons”may often be on the verge of not being rec-
ognized, whereas the splicing machinery easily recognizes other well-
deﬁned exons. Since the primary determinants for exon deﬁnition is
the strength of their ﬂanking splice sites, we ﬁrst evaluated the splice
sites of all exons of the PAH gene. From this analysis exon 11 clearly
stood out by having the weakest 3′ splice site of all exons of the PAH
gene, andwe therefore hypothesized that exon 11 could be a vulnerable
exon to aberrant mRNA processing. This is further corroborated by the
fact that mutations that only very modestly affected splice site strength
had been reported to cause aberrant splicing of exon 11 [13,18] Conse-
quently, we investigated in more detail how exonic mutations may af-
fect PAH exon 11 splicing.
Analysis of patient cells showed that both c.1066-3C>T and a mis-
sense mutation, c.1144T>C cause exon 11 skipping. This corroborates
our hypothesis that exon 11 is vulnerable and exempliﬁes that simple
comparison of splice site strength may help to identify vulnerable
exons. Moreover, we demonstrate that NMD may lead to an underesti-
mation of the degree of exon11 skippingwhen analyzing patient derived
cell lines. Similar analyses of patient cells may therefore easily overlook
exon 11 skipping if NMD is not blocked prior to analysis. In order to
enable investigation of patient mutations without the need of obtaining
cells and to enable analysis of exon 11 splicing in more detail we
established a minigene, which closely mimics the endogenous PAH
gene.Minigenes conﬁrmed that the c.1144T>Cmutation affects splicing;
moreover our testing of other artiﬁcial mutations (like c.1139C>G,
c.1144T>G and c.1146C>A) shows that other exonic variants lead to
exon 11 skipping. Minigene assessment demonstrated that the patient
mutations c.1139C>T and c.1169A>G do not affect splicing. Our muta-
genesis of the minigene showed very clearly, that it is the weak 3′ splice
site that is responsible for the vulnerability of exon 11, since increasing
the splice site strength by optimization of the polypyrimidine tract neu-
tralized the effect of all the splicing mutations.
The c.1066-3C>T mutation has been ﬁrst reported by Abadie et al.
[18]. The PAH ampliﬁcation byRT-PCR from lymphoblast cells of their pa-
tient revealed two different transcripts, corresponding to normal spliced
PAH and exon 11 skipped PAH transcripts. However, the patient was
compound heterozygous for p.R261Q/c.1066-3C>T and the normal PAH
transcript may exclusively result from p.R261Q allele. A BH4-responsive,
homozygous c.1066-3C>T patient has been reported by Desviat et al.
[26].Wewere not able to detect normal spliced PAH transcript in our ho-
mozygous patient for c.1066-3C>T. In addition, our patient was not
responding to BH4 in an 8 h test. To our knowledge, PAH gene transcript
ampliﬁcation from a homozygous patient was not reported before. Lym-
phoblasts are not the primary tissue for PAH protein expression, but we
speculate that very small amounts of normal spliced PAH transcript could
be present in the liver. Faint bands observed in our transfected COS-1 and
Chang cells indicate that low amounts of normally spliced PAH can be
produced from the c.1066-3C>T. Even low amounts of PAH transcript
would be stabilized by BH4 and result in lowered Phe levels upon BH4
treatment.
Because testing mutations using minigenes and/or patient cells is
cumbersome there is a growing need for computer-based predictions of




Fig. 5. SF2/ASF overexpression in COS-1 cells transfected with PAH minigenes leads to pseudoexon activation.(A) Schematic overview of PAH splicing showing inclusion of a
pseudoexon sequence from intron 11. (B) Analysis of COS-1 cells transfected with minigenes harboring WT, c.1139C>T, c.1144T>C, c.1066-3C>T and c.1169A>G mutations
with and without co-transfection of a vector overexpressing SF2/ASF. (C) Analysis of COS-1 cells transfected with minigenes harboring WT, c.1144T>C and c.1066-3C>T mutations
with and without and optimized 3′ splice site and co-transfection of a vector overexpressing SF2/ASF. Ampliﬁcation of PAH exons 10–12 was done with minigene-speciﬁc primers.
Transfection experiments were performed as at least two independent transfections.
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program simultaneously analyzes wild type and mutant sequences for
changes in splicing regulatory sequences and theoretical binding motifs
for splicing factors. Although, such programs may provide useful hints
to potential regulatory sequence motifs, which are changed by a muta-
tion, the present study demonstrates that predictions cannot be used un-
critically and that the different algorithms may produce contradictory
predictions. In the present study the c.1139C>T mutation is predicted to
be deleterious, instead it seems to improve splicing, which demonstrates
why functional testing is still warranted. Alternatively, HSF predictions
concerning the c.1144T>Cmutation and in particular identifying TTCCAG
(c.1144–c.1148) as an ESE may be correct. The importance of this se-
quence is further demonstrated by the fact that it is conserved in species
raging from elephants to mice (Fig. 6). Moreover, comparison with our
database of other exonic splicing mutations (unpublished observation)
showed that a G>T SNP in exon 4 of the CYP2B6 gene (rs3745274) [27],
which causes aberrant splicing, disrupts the samemotif at a different po-
sition (TTCCAG), and is also predicted to be deleterious by HSF. This indi-
cates that cis-acting motifs are general and may be functional in other
genes. On the other hand, the well-characterized ESE from the ACADM
gene [17,24] has been demonstrated to function in other genes, failed to
replace the endogenous PAH ESE sequence. The failure of the ACADM
ESE shows that motifs are not completely interchangeable, but that
there are exon-speciﬁc requirements, possibly reﬂecting the need for re-
cruitment of different splicing regulatory proteins. Our preliminary at-
tempts to identify the factor(s) that binds to the PAH ESE spanning
position c.1144 were not conclusive, although they very clearly showed
that there were dramatic differences in the binding of important splicing
regulatory proteins to wild type and mutant PAH sequences.
We conclude that our study shows that exon 11 of the PAH gene is a
vulnerable exon due to its weak 3′ splice site and that this makes exon
11 inclusion dependent on an ESE spanning position c.1144. Important-
ly, this implies that also a number of other mutations in exon 11 are
likely to affect splicing, since splicing is often determined by a ﬁne bal-
ance between several positive and negative splicing regulatory ele-
ments distributed throughout the exon. It is therefore important to
assess the effect of all mutations in exon 11 on splicing by using our
establishedminigene, since suchmutations that disrupt splicing are un-
likely to facilitate response to BH4 and if not recognized their effect on
splicing may lead to inconsistent genotype–phenotype correlations.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.ymgme.2012.05.013.
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